Background: This study reviews the outcomes of retransplantation using living-donor right-liver grafts.
Methods: A retrospective study of liver retransplants performed between 1996 and 2013 was conducted. The retransplants were divided into the DD group (with deceased donors) and the LD group (with living donors). Survival outcomes were analyzed.
Results: The DD group contained 23 patients and 27 retransplants using whole-liver grafts and the LD group contained 11 patients and 11 retransplants using right-liver grafts. Vascular and biliary complications were the main indications for retransplantation in both groups. The LD group had significantly younger donors, lighter grafts, shorter cold ischemia and longer operations. The two groups were comparable in age, preoperative liver function, warm ischemia, blood loss, transfusion, intensive care unit stay, hospital stay, hospital mortality, complication and graft loss. The 1-year, 3-year and 5-year patient survival rates were 78.3%, 73.7% and 63.8%, respectively, in the DD group. The LD group had the corresponding rates all at 90.9% (P = 0.246). The 1-year, 3-year and 5-year graft survival rates were 74.1%, 65.8% and 61.5%, respectively, in the DD group. The LD group had the corresponding rates all at 90.9% (P = 0.132).
Conclusion: Excellent long-term survival after retransplantation using living-donor right-liver grafts can be achieved.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jhbp.100 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world cost-effectiveness analysis of thymoglobulin versus no induction therapy in kidney transplant recipients at low risk of graft loss.
J Bras Nefrol
January 2025
Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, SP, Brazil.
Background: A new induction therapy strategy of a single 3 mg/kg dose of rabbit antithymocyte globulin (r-ATG) showed a lower incidence of acute rejection.
Methods: The objective of this study was to use real-world data to determine the incremental cost-effectiveness ratio (ICER) of r-ATG induction for the prevention of acute rejection (AR) in the first year following kidney transplantation and for kidney graft survival over 1, 4, and 10 years of post-transplantation from the perspective of the national public healthcare system. A Markov state transition model was developed utilizing real-world data extracted from medical invoices from a single center.
Small for Size Syndrome in Living Donor Liver Transplantation- Prevention and Management.
J Clin Exp Hepatol
November 2024
Institute of Liver Disease & Transplantation, Gleneagles Health City, Chennai, India.
Small-for-size syndrome is a clinical syndrome of early allograft dysfunction usually following living donor liver transplantation due to a mismatch between recipient metabolic and functional requirements and the graft's functional capacity. While graft size relative to the recipient size is the most commonly used parameter to predict risk, small-for-size syndrome is multifactorial and its development depends on a number of inter-dependant factors only some of which are modifiable. Intra-operative monitoring of portal haemodynamics and portal flow modulation is widely recommended though there is wide variation in clinical practice.
View Article and Find Full Text PDFEnterococcus avium Infection After Liver Transplantation in Vietnam: A Case Report.
Transplant Proc
December 2024
Institute of Biomedicine and Pharmacy, Vietnam Military Medical University, Hanoi, Vietnam. Electronic address:
Background: The infectious complications are the most common and can be life-threatening to liver transplant recipients, in particular, within the first month after transplantation. Early diagnosis of these severe complications and accurate detection of causative etiologies are crucial for the choice of therapeutic strategies and management of liver transplants.
Case Report: We present a case report of a patient with a history of primary sclerosing cholangitis who underwent a liver transplantation (LT) from a living donor.
Role of the Lymphocyte Count-to-C-Reactive Protein Ratio in the Risk Stratification for High EASE Scores After Living Donor Liver Transplantation: A Retrospective Observational Cohort Study.
J Clin Med
December 2024
Department of Anesthesiology and Pain Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Early allograft failure (EAF) significantly contributes to mortality, necessitating re-transplantation following liver transplantation. The EAF simplified estimation (EASE) score has been recently developed to predict EAF. We aimed to assess the predictive capacity of high EASE scores for EAF and postoperative outcomes and to evaluate the association between the lymphocyte count-to-C-reactive protein ratio (LCR) and high EASE scores after living donor liver transplantation (LDLT).
View Article and Find Full Text PDFEarly relaparotomy in recipients after living donor liver transplantation: causes, risk factors, and consequences.
Turk J Med Sci
October 2024
Department of General Surgery, Faculty of Medicine, İnönü University, Malatya, Turkiye.
Article Synopsis
- The study investigates the reasons behind early relaparotomies in living donor liver transplant recipients within the first 30 days post-surgery, emphasizing the ongoing prevalence of complications despite improved surgical practices.* -
- Out of 535 patients analyzed between 2019 and 2021, 15.9% (85 patients) required early relaparotomy, with key factors like elevated creatinine and sodium levels, the use of left lobe grafts, and significant blood loss identified as independent risk factors.* -
- Major causes for needing early relaparotomy included postoperative bleeding, biliary leakage, and vascular issues, highlighting the complexities of post-transplant care and the importance of monitoring at-risk patients.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!